HCMNasdaqPharmaceutical PreparationsAlso trades as HMDCF
HUTCHMED (China) Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 5, 2026
$14.18+0.13 (+0.93%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 27.3
- Dividend yield
- –
HUTCHMED (China) Ltd revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oncology/Immunology segment | $285.54M | $363.37M | $528.62M | $163.84M | $119.61M | $30.22M | $26.79M | $41.23M | – | – | 52.1% | -21.4% |
| Other Ventures segment | $262.97M | $266.84M | $309.38M | $262.57M | $236.52M | $197.76M | $178.10M | $172.88M | – | – | 47.9% | -1.4% |
| Commercial Platform | – | – | – | – | – | – | $188.86M | $176.46M | $205.21M | $180.85M | – | – |
| Innovation Platform | – | – | – | – | – | – | $16.03M | $37.65M | $36.00M | $35.23M | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Invoiced Goods-Distribution | $262.97M | $266.84M | $309.38M | $262.57M | $236.52M | $197.76M | $175.51M | $161.22M | $203.35M | – | 47.9% | -1.4% |
| Invoiced Goods-Marketed Products | $100.64M | $128.01M | $83.09M | $57.06M | $33.94M | $11.33M | $8.11M | $3.32M | – | – | 18.3% | -21.4% |
| Other collaboration revenue -royalties | $68.42M | $71.04M | $32.47M | $26.31M | $15.06M | $4.89M | $2.65M | $261.00K | – | – | 12.5% | -3.7% |
| Services-Commercialization of Marketed Products | $45.30M | $52.49M | $48.61M | $41.28M | $27.43M | $3.73M | $2.58M | $11.66M | – | – | 8.3% | -13.7% |
| License & Collaborations-Manufacturing supply | $31.19M | $10.39M | $4.72M | – | – | – | – | – | – | – | 5.7% | +200.1% |
| Services -collaboration research and development | $27.90M | $57.97M | $80.40M | $23.74M | $19.00M | $9.77M | $15.53M | $17.68M | – | – | 5.1% | -51.9% |
| License & Collaborations-Licensing | $12.09M | $43.00M | $278.86M | $14.95M | $23.66M | – | – | $12.14M | – | – | 2.2% | -71.9% |
| Goods | – | – | – | – | – | – | – | $164.54M | $203.35M | $180.85M | – | – |
| Services | – | – | – | – | – | – | $18.61M | $37.17M | $28.40M | $25.30M | – | – |
| Milestones | – | – | – | – | – | – | – | – | $9.46M | $9.93M | – | – |
| Licenses | – | – | – | – | – | – | – | $12.14M | – | – | – | – |
| Royalties | – | – | – | – | – | – | $2.65M | $261.00K | – | – | – | – |
| Goods-Innovative Medicines | – | – | – | – | – | – | $8.11M | $3.32M | – | – | – | – |
| Services-Research and development | – | $471.00K | $481.00K | $507.00K | $525.00K | $491.00K | $494.00K | $7.83M | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China | $407.45M | $452.41M | $484.90M | $426.41M | – | – | – | – | – | – | 74.3% | -9.9% |
| US and others | $141.06M | $177.79M | $353.10M | – | – | – | – | – | – | – | 25.7% | -20.7% |
From the segment and revenue-disaggregation notes of HUTCHMED (China)'s 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.